Menopause affects millions of women around the world each year, yet many people still underestimate how disruptive its symptoms can be.
Although menopause is a natural biological process, the changes it brings can affect physical health, emotional wellbeing, sleep quality, work performance, and everyday activities.
Among the most common complaints are hot flashes and night sweats. These symptoms occur because changing hormone levels affect the body’s internal temperature control system.
A hot flash can appear suddenly and create intense feelings of heat, sweating, flushing, and discomfort. Some women experience only occasional episodes, while others may have multiple hot flashes every day.
The effects often extend beyond temperature changes. Women who experience frequent hot flashes may struggle with interrupted sleep, fatigue, irritability, difficulty concentrating, anxiety, and depression. Because of this, finding effective treatments remains an important goal for doctors and researchers.
Traditionally, hormone replacement therapy has been considered one of the most effective ways to manage menopausal symptoms.
However, hormone therapy is not suitable for everyone. Some women have health conditions that limit its use, while others prefer to avoid hormones altogether. As a result, interest in nonhormonal therapies has grown rapidly.
One of the newest nonhormonal treatments available is fezolinetant, a medication approved by the U.S. Food and Drug Administration. Unlike hormone therapy, fezolinetant works by targeting nerve pathways in the brain that help regulate body temperature. This allows it to reduce hot flashes without directly affecting hormone levels.
A new study presented at ENDO 2026, the Endocrine Society’s annual scientific meeting in Chicago, provides encouraging evidence about how this treatment performs in real-world settings.
The research was led by Pauline M. Maki from the University of Illinois Chicago College of Medicine. According to the researchers, the study is the first to examine the real-world effects of nonhormonal menopause treatments on symptoms such as hot flashes, anxiety, depression, and sleep-related problems.
The study included 656 women between the ages of 40 and 75 who were experiencing troublesome menopausal symptoms. Participants had recently started treatment with one of several nonhormonal therapies. The largest groups received either fezolinetant or antidepressant medications known as SSRIs and SNRIs. Other participants used medications such as gabapentin and oxybutynin.
Researchers followed participants for twelve weeks and measured changes in menopausal symptoms as well as emotional wellbeing. They evaluated symptoms at four, eight, and twelve weeks after treatment began.
Among the 201 women using fezolinetant, improvements appeared quickly. Hot flashes and night sweats became significantly less bothersome within four weeks. Benefits continued to increase through eight and twelve weeks.
Importantly, emotional health improved as well. Symptoms of depression and anxiety declined significantly during the study period. These improvements were visible after only four weeks and continued throughout the twelve-week follow-up.
Women taking SSRIs, SNRIs, and other nonhormonal treatments also experienced improvements in mood and anxiety symptoms. However, the study demonstrated that fezolinetant provided benefits similar to those previously reported in clinical trials.
This finding is particularly meaningful because real-world studies often provide a more accurate picture of how medications perform in everyday medical practice.
Clinical trials typically include carefully selected participants who meet strict eligibility criteria. Real-world studies involve more diverse patient populations and can reveal whether treatments remain effective outside highly controlled research environments.
The results may offer reassurance to women seeking alternatives to hormone therapy. Many women want effective symptom relief but may be concerned about hormones or unable to use them. Fezolinetant appears to provide another option that can address both physical and emotional symptoms associated with menopause.
The study also reinforces the close relationship between menopausal symptoms and mental health. Poor sleep, repeated hot flashes, and ongoing discomfort can affect mood and emotional resilience. Reducing these symptoms may create broader improvements in quality of life.
There are several strengths to the research. The study included a relatively large number of participants and focused on real-world outcomes. This increases the practical relevance of the findings for patients and healthcare providers.
However, some limitations should also be considered. The research was sponsored by industry, and the results were presented at a scientific meeting rather than in a fully published peer-reviewed journal article. Additional studies, especially independent research, will help confirm the long-term benefits and safety of treatment.
Even with these limitations, the findings suggest that fezolinetant is becoming an important addition to the range of available menopause treatments. As awareness of menopause-related health challenges continues to grow, effective nonhormonal therapies may help many women manage symptoms and maintain a better quality of life.
Review and analysis: This study strengthens evidence that fezolinetant works not only in clinical trials but also in routine medical care. The improvements in mood and anxiety are particularly noteworthy because menopause often affects emotional wellbeing as much as physical comfort.
While more independent studies are needed, the findings suggest that nonhormonal therapies may play a growing role in helping women manage menopause safely and effectively.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and vitamin D supplements could strongly reduce cancer death.
For more information about health, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing higher intake of dairy foods linked to higher prostate cancer risk.
Source: University of Illinois Chicago.
